HCV Warning For ESAs Could Raise Questions For Pipeline Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Warning on red cell aplasia and anemia for Procrit and Aranesp in hepatitis C patients could have implications for boceprevir and telaprevir.